Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1.

Background:Sirolimus is an inhibitor of mammalian target of rapamycin, which exhibits large interindividual pharmacokinetic variability. We report sirolimus pharmacokinetic data collected as part of a concentration-controlled multicenter phase II clinical trial in pediatric patients with neurofibrom